Jane Street Group LLC Has $296,000 Holdings in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Jane Street Group LLC lessened its position in shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) by 5.2% in the third quarter, according to its most recent filing with the SEC. The firm owned 103,427 shares of the company’s stock after selling 5,663 shares during the quarter. Jane Street Group LLC owned approximately 0.11% of Poseida Therapeutics worth $296,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Fred Alger Management LLC acquired a new stake in Poseida Therapeutics during the 3rd quarter valued at approximately $369,000. Connor Clark & Lunn Investment Management Ltd. increased its position in Poseida Therapeutics by 62.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 359,197 shares of the company’s stock valued at $1,027,000 after purchasing an additional 138,510 shares during the period. Renaissance Technologies LLC increased its position in Poseida Therapeutics by 53.4% during the 2nd quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock valued at $2,496,000 after purchasing an additional 297,500 shares during the period. Advantage Alpha Capital Partners LP acquired a new stake in Poseida Therapeutics during the 3rd quarter valued at approximately $285,000. Finally, Charles Schwab Investment Management Inc. increased its position in Poseida Therapeutics by 3.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 567,063 shares of the company’s stock valued at $1,622,000 after purchasing an additional 21,255 shares during the period. Institutional investors and hedge funds own 46.87% of the company’s stock.

Poseida Therapeutics Stock Performance

NASDAQ PSTX opened at $9.50 on Friday. The company has a fifty day simple moving average of $7.37 and a 200 day simple moving average of $4.47. Poseida Therapeutics, Inc. has a 12-month low of $1.87 and a 12-month high of $9.67. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.68. The company has a market cap of $928.85 million, a P/E ratio of -15.08 and a beta of 1.63.

Insider Buying and Selling at Poseida Therapeutics

In other Poseida Therapeutics news, Chairman Mark J. Gergen sold 30,000 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $9.46, for a total transaction of $283,800.00. Following the transaction, the chairman now directly owns 651,291 shares in the company, valued at approximately $6,161,212.86. This trade represents a 4.40 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 2.90% of the company’s stock.

Wall Street Analyst Weigh In

PSTX has been the subject of several recent analyst reports. BTIG Research reaffirmed a “neutral” rating on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. Piper Sandler downgraded shares of Poseida Therapeutics from an “overweight” rating to a “neutral” rating and set a $10.00 price objective for the company. in a research report on Monday, December 2nd. HC Wainwright reaffirmed a “neutral” rating and set a $9.00 price objective (down previously from $20.00) on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. Cantor Fitzgerald downgraded shares of Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 26th. Finally, William Blair reaffirmed a “market perform” rating on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. Five research analysts have rated the stock with a hold rating, According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $9.50.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.